Allurion Technologies, an established leader in the development of innovative, proven, and trusted weight loss experiences, today—on World Obesity Day—announced its commitment to treat 40,000 individuals around the world and shed over one million pounds by the end of 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005038/en/
Allurion’s Elipse® Program features the Elipse Balloon—the world’s first and only procedureless™ medical device for weight loss—and a Bluetooth® body composition scale that pairs with Allurion’s smartphone app to provide a 360-degree consumer experience. Unlike other weight loss balloons on the market, the Elipse Balloon is designed to be placed and removed without surgery, endoscopy, or anesthesia. It is swallowed in a capsule during an outpatient office visit and is designed to remain in the stomach for approximately four months, after which it opens and passes naturally from the body.
Worldwide, there are 2 billion people who are overweight and recent projections indicate that number will grow to 3 billion by 2030.1 In the United States, there are 70 million adults with obesity today and by 2030, half of the American population—or 100 million adults—will suffer from obesity.2 According to the McKinsey Global Institute, obesity is responsible for about 5 percent of all deaths annually worldwide, and its global economic impact amounts to roughly $2 trillion annually, or 2.8 percent of global GDP—nearly equivalent to the global impact of smoking or of armed violence, war, and terrorism.
“People all over the world are embracing the convenience and effectiveness of our novel approach to weight loss,” said Shantanu Gaur, M.D., co-founder and CEO of Allurion Technologies, Inc. “On World Obesity Day, we celebrate the success of those whose lives have changed as a result of the Elipse Program and set a bold goal for our company for the year ahead.”
“The Elipse Program offers a weight loss solution that is proven and less invasive than the alternatives,” said Jan W. M. Greve, MD, PhD, Professor of metabolic and bariatric surgery Maastricht University Medical Center in the Netherlands. “Many patients living with obesity have tried numerous programs that have been unsuccessful in helping them reach their weight loss goals. The Elipse Program not only delivers the weight loss but does so in a manner that helps patients change their lifestyle and behavior in the process.”
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize their full potential with innovative, scalable and trusted experiences. The company’s flagship product, the Elipse Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss. Learn more about the Elipse Balloon and Allurion online at www.allurion.com, on Facebook at www.fb.com/allurion or on Twitter @alluriontech.
1 Kelly et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (London). 2008;32(9):1431-7.
2 Ward et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. NEJM. 2019;381:2440-50.